|Principal Investigator/ Physician||Weisi Yan, MD|
|Protocol No.||RTOG 0924|
|Contact Email||MCI Clinical Trials|
Protocol Title: "Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial."
Inclusion Criteria: Pathologically proven diagnosis of prostatic adenocarcinoma within 180 days of registration; clinically negative lymph nodes as established by imaging within 90 days prior to registration; no evidence of bone metastases; Zubrod performance status 0-1
Exclusion Criteria: Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for 3 years; previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
Clinical Trails.Gov Link: https://clinicaltrials.gov/ct2/show/NCT01368588?term=RTOG+0924&rank=1
© 2018 USA Health